Rachel Klemovitch, Assistant Editor01.25.24
Confluent Medical Technologies announced its partnership with ATI to invest more than $50 million over the next several years in ATI’s Nitinol melt and materials conversion infrastructure.
This investment will triple ATI’s capacity for medical Nitinol. Confluent will act as a fulfillment partner, providing value-add services and order-fulfillment for ATI medical Nitinol mill product.
“The growth in Neurovascular, Electrophysiology, Structural Heart, Peripheral Vascular, and Orthopedic device markets is driving an 18% growth rate (CAGR) in Nitinol demand. Given the substantial equipment and infrastructural cost needed to increase supply chain capacity, the industry has struggled to support this growth,” stated Confluent president and CEO Dean Schauer.
“ATI is honored to partner with Confluent in producing what is literally a life-saving material,” said ATI Specialty Alloys & Components business president Rob Foster. “We appreciate the value Confluent places on our expertise and capabilities as the industry leader in Nitinol production. Confluent’s investment in ATI’s growth will ensure the stable supply of Nitinol the industry needs for growth.”
Schauer added, “Our investment in this critical infrastructure will provide the necessary mid-term and long-term melt and conversion capacity necessary to meet and support Nitinol material demand. As the most trusted supply partner for our OEM customers, Confluent is pleased to be making this investment in creating a reliable supply chain so that OEMs can continue providing life-saving devices in these specialized markets.”
ATI will expand its Millersburg, Oregon facility with the expectation to be operational in 2027. These capacity investments and expanded capabilities will help deliver ATI’s Medical Nitinol services in tubes, wires, hollows, mill products, and components.
This investment will triple ATI’s capacity for medical Nitinol. Confluent will act as a fulfillment partner, providing value-add services and order-fulfillment for ATI medical Nitinol mill product.
“The growth in Neurovascular, Electrophysiology, Structural Heart, Peripheral Vascular, and Orthopedic device markets is driving an 18% growth rate (CAGR) in Nitinol demand. Given the substantial equipment and infrastructural cost needed to increase supply chain capacity, the industry has struggled to support this growth,” stated Confluent president and CEO Dean Schauer.
“ATI is honored to partner with Confluent in producing what is literally a life-saving material,” said ATI Specialty Alloys & Components business president Rob Foster. “We appreciate the value Confluent places on our expertise and capabilities as the industry leader in Nitinol production. Confluent’s investment in ATI’s growth will ensure the stable supply of Nitinol the industry needs for growth.”
Schauer added, “Our investment in this critical infrastructure will provide the necessary mid-term and long-term melt and conversion capacity necessary to meet and support Nitinol material demand. As the most trusted supply partner for our OEM customers, Confluent is pleased to be making this investment in creating a reliable supply chain so that OEMs can continue providing life-saving devices in these specialized markets.”
ATI will expand its Millersburg, Oregon facility with the expectation to be operational in 2027. These capacity investments and expanded capabilities will help deliver ATI’s Medical Nitinol services in tubes, wires, hollows, mill products, and components.